Select to view the solutions available in your location.
Track orders, get results, manage personal information, and more.
Order tests, track orders, get results, and more.
Learn more about our innovative products and services that help detect cancer earlier and power smarter treatment decisions.
Exact Sciences plans to introduce the Cologuard Plus™ test in 2025, building on a decade of patient impact.
Find out how our scientific rigor, quality standards, and development of future tests make us a leader in cancer testing and treatment guidance.
How one revolutionary test could change the health of millions.
Learn all about Exact Sciences, including our purpose, the people who drive it, our history, and the impact we’ve made.
Several Exact Sciences initiatives address disparities in cancer outcomes among U.S. Latinos.
Explore stories, news, and events that highlight our innovation, technology, and people fighting cancer on all fronts.
A message from Exact Sciences Corporation Chief Medical Officer of Screening
Recent media reports inaccurately implied colonoscopies are ineffective at reducing colorectal cancer deaths, per a study published in the New England Journal of Medicine. The headlines fail to tell the real story.
Based on the forty-two percent of study participants who received a colonoscopy, the mortality rate was cut in half and the risk of developing colorectal cancer decreased by 31 percent.
Colonoscopies remain a crucial tool for colorectal cancer screening. Studies also show the importance of offering more than one FDA-approved screening option, including the U.S. Preventive Services Task Force endorsed, non-invasive, at-home tests such as Cologuard®, which detects both colorectal cancers and precancerous polyps. If you’re 45 or older and at average risk for colorectal cancer, speak with your healthcare provider about your options for screening.
Exact Sciences
Read more »
Jenny Price